Other potential uses: addiction, dementia, cancer Mike Haney: We mentioned before some of the other sort of non-weight benefits that we're seeing with this
Circumference Measurements: Weekly measurements of waist, hips, thighs, and arms using consistent technique (same time of day, same measurement points) track regional changes that correlate with fat loss
Seek urgent medical help if you experience: severe or continuous abdominal pain persistent vomiting or inability to keep fluids down signs of infection (fever, redness, swelling) shortness of breath , chest pain , or sudden weakness Both treatments must be taken under medical supervision

Typical PA requirements include: Confirmed diagnosis of type 2 diabetes or obesity Documented BMI (often 30 or 27 with comorbidities) Failed trials of other medications Lifestyle modification attempts Recent A1C lab values (for diabetes) Documentation Must Include Height and weight with calculated BMI Diagnosis supporting medical necessity Treatment plan Follow-up and monitoring plan Compliance & Audit Risk GLP-1 medications are a high-risk audit target due to: Rapid growth in utilization High drug cost Off-label prescribing Weight-loss demand Common audit issues: Incorrect diagnosis codes Missing BMI documentation Lack of medical necessity Billing weight-loss drugs to Medicare Inappropriate use of unclassified J-codes Medicare Coverage Rules Medicare Part D generally does not cover weight-loss drugs , even if FDA-approved for obesity
Cancers (Basel), 2024
Key Advantages: Targets hypothalamus-pituitary-gonadal axis directly, supports natural hormone signaling, short-term use efficacy